All News

ASH 2025 highlighted innovative cancer treatments, including in vivo CAR T therapy and options that enhance quality of life while reducing burdens.

Jonathan Strober, MD, discusses promising results from the VIBRANCE-MG trial, highlighting nipocalimab's safety and efficacy for pediatric myasthenia gravis.

From cutting-edge AI detection tools to rising incidence in younger adults and threats to free screenings, 2025 brought major shifts in the struggle against colorectal cancer.

The top ophthalmology content included FDA approvals, FDA complete response letters, and new associations between cataracts and antioxidant index.

Alopecia areata significantly impacts quality of life, driven by appearance-related anxiety related to where hair loss occurs more than how much is lost.

In the EPCORE DLBCL-3 study, fixed-duration epcoritamab monotherapy delivered deep, durable responses with manageable toxicity in older, chemotherapy-ineligible patients with LBCL.

Explore the top 5 insights on managed care, public health policy, and emerging health trends shaping 2025's health care landscape.

This year’s most-read articles on CLL highlighted research and insights on personalized therapy, long-term remission, and next-generation cell treatments.

Highlights from EHA 2025 included use of bispecific antibodies in more settings and novel approaches for improving outcomes in hard-to-treat patients.

Obstructive sleep apnea significantly worsens mental health in older adults, increasing risks of depression and psychological distress over time.

Respiratory syncytial virus (RSV) remains a leading cause of acute bronchitis in children, but new research may enable earlier intervention.

Leadership shakeups at the CDC, legal challenges, and growing scrutiny of the childhood immunization schedule have disrupted US vaccine policy.

Here are our top highlights from AAD 2025 that include safety of topical JAK inhibitors, climate impacts on skin health, affordability of classic therapies, and advancing AI in dermatology.

This year's most-watched video evaluated how President Donald Trump's rescission of several Biden-era executive orders may impact Medicaid and Medicare initiatives.

A recent review suggests women with ovarian or colorectal cancer face a higher risk of developing the other, highlighting the need for surveillance.

Check out the most popular stories and developments that happened in mental health care this year.

In-home step training for multiple sclerosis showed no improvement in ankle proprioception or muscle performance, highlighting challenges in exercise adherence.

Explore the latest breakthroughs in allergy treatments, including FDA approvals and emerging therapies that enhance patient care and address systemic challenges.

Baricitinib shows promising results for severe alopecia areata, with more than half of patients experiencing significant hair regrowth within a year.

Real-world evidence highlights the effectiveness of lisocabtagene maraleucel in treating relapsed or refractory chronic lymphocytic leukemia (R/R CLL).

Chronic inducible cold urticaria is rare, but a new study suggests it can have significant impacts on patients’ daily lives.

Patients with generalized myasthenia gravis face significant barriers to diagnosis, creating the need for improved patient–health care interactions.

From oncology to cardiology, Institute for Value-Based Medicine® conversations highlighted the ways value-based care is reshaping access, equity, and outcomes.

Chronic kidney disease complicates cancer treatment, leading to reduced chemotherapy use. Personalized approaches are essential for optimal patient outcomes.

Readers of PHEO this year found value in research, conference coverage, and insights that touched on health outcomes and care quality.

Obstructive sleep apnea may increase Parkinson disease risk, but early CPAP treatment could significantly reduce this risk.

Angela Liu, PhD, MPH, speaks about her study that examined mental health care use by Medicare beneficiaries before and after switching from MA to TM.

Our conference coverage featured updates on clinical trials testing new treatments for NSCLC, bladder cancer, and breast cancer.